Document Detail


Assessment of myocardial viability in ischemic heart disease by cardiac magnetic resonance imaging.
MedLine Citation:
PMID:  18319702     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Assessment of myocardial viability aims at differentiating between viable and non-viable myocardium. The proof of dysfunctional but viable myocardium is crucial to predict outcome of revascularization after acute (AMI) and chronic myocardial infarction (CMI). Cardiac magnetic resonance imaging (CMRI) offers different options to detect viable myocardium: Measurements of end-diastolic wall thickness by cine-CMRI can be used to depict chronically scarred myocardium, but fails to detect acute myocardial necrosis. Low-dose dobutamine stimulation (LDDS) cine-CMRI analyses the contractile reserve of dysfunctional but viable myocardium under pharmacologic stimulus to identify viable myocardium in AMI and CMI with high specificity. Sensitivity of LDDS cine-CMRI is superior to LDDS echocardiography but reduced in patients with severely impaired left ventricular (LV) function. The delayed-enhancement (DE) technique directly visualises non-viable myocardium due to an altered contrast-media distribution in necrotic and fibrotic tissue. DE-CMRI identifies non-viable myocardium with high spatial resolution independently from LV function. The transmural extent of contrast enhancement in DE-CMRI is used to predict functional recovery after revascularization in AMI and CMI. Furthermore, the amount and pattern of contrast enhancement in DE-CMRI provide important prognostic information in both entities. Recent studies demonstrated the superiority of DE-CMRI compared to single photon emission tomography (SPECT) and positron emission tomography (PET) to assess myocardial viability. Therefore, DE-CMRI is currently recognised as the standard of reference for assessment of myocardial viability. The technical background, clinical application and accuracy of the different CMRI techniques to assess myocardial viability in AMI and CMI are discussed in this work.
Authors:
K Muellerleile; A Barmeyer; M Groth; G K Lund
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Minerva cardioangiologica     Volume:  56     ISSN:  0026-4725     ISO Abbreviation:  Minerva Cardioangiol     Publication Date:  2008 Apr 
Date Detail:
Created Date:  2008-03-05     Completed Date:  2008-07-31     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0400725     Medline TA:  Minerva Cardioangiol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  237-49     Citation Subset:  IM    
Affiliation:
Center for Cardiology and Cardiovascular Surgery, University Medical Center Hamburg-Eppendorf Hamburg, Germany. kaiml@web.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Dobutamine / diagnostic use
Humans
Image Processing, Computer-Assisted / methods
Magnetic Resonance Imaging / methods*
Myocardial Infarction / diagnosis
Myocardial Ischemia / diagnosis*
Myocardium / pathology*
Predictive Value of Tests
Sensitivity and Specificity
Chemical
Reg. No./Substance:
34368-04-2/Dobutamine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Measuring left ventricular mechanical dyssynchrony from ECG-gated SPECT myocardial perfusion imaging...
Next Document:  Telecardiogram: still of matter in the modern cardiac imaging era?